Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

Kei Muro, MD
Published: Thursday, Feb 02, 2017



Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

This multinational, randomized, phase III trial of the combination of capecitabine and irinotecan (XELIRI) evaluated safety with or without bevacizumab (Avastin) versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic CRC.

Results showed that bevacizumab did not change safety profiles in either the XELIRI or FOLFIRI arms. Both were both well tolerated, says Muro, with incidence of toxicities slightly lower in the XELIRI arm at 53.2% compared with 73% in the FOLFIRI arm.
 


Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

This multinational, randomized, phase III trial of the combination of capecitabine and irinotecan (XELIRI) evaluated safety with or without bevacizumab (Avastin) versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic CRC.

Results showed that bevacizumab did not change safety profiles in either the XELIRI or FOLFIRI arms. Both were both well tolerated, says Muro, with incidence of toxicities slightly lower in the XELIRI arm at 53.2% compared with 73% in the FOLFIRI arm.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x